Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571324 · ClinicalTrials.gov registry record · Phase 1
Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
A Phase 1 study, sponsored by Diva De Leon.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00571324 is a Phase 1 study that has completed, run by Diva De Leon. The registered enrollment target is 9 participants.
The verdict
NCT00571324, a Phase 1 study, has completed, sponsored by Diva De Leon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.
Interventions
- OTHER Vehicle
- DRUG Exendin-(9-39)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571324
The ClinicalTrials.gov registry entry for NCT00571324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diva De Leon, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT00571324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571324 about?
NCT00571324 is a clinical study titled "Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism". The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.
What is the current status of trial NCT00571324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00571324?
The interventions under investigation include: Vehicle (OTHER), Exendin-(9-39) (DRUG).
Who is sponsoring clinical trial NCT00571324?
This trial is sponsored by Diva De Leon, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.